We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SRT3.F

Price
216.90
Stock movement up
+3.40 (1.59%)
Company name
Sartorius Aktiengesellschaft
Exchange
(F
,
Currency
EUR
)
Sector
Healthcare >
Medical Instruments & Supplies
Markedsværdi
7.55B
Ent værdi
13.09B
Pris/omsætning
2.26
Pris/bog
1.98
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
0.03%
Efterfølgende P/E
97.29
Fremtidig P/E
42.66
PEG
-
EPS-vekst
7.73%
1 års afkast
-1.86%
3 års afkast
-13.92%
5 års afkast
-7.33%
10 års afkast
17.44%
Senest opdateret: 2025-06-22

UDBYTTE

SRT3.F betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E97.29
Pris til OCF9.01
Pris til FCF21.56
Pris til EBITDA41.60
EV i forhold til EBITDA72.12

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning2.26
Pris til egenkapital1.98
EV i forhold til salg3.92

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier34.81M
EPS (TTM)1.12
FCF pr. aktie (TTM)5.07

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)3.34B
Bruttofortjeneste (TTM)1.48B
Driftsindkomst (TTM)467.80M
Nettoindkomst (TTM)77.60M
EPS (TTM)1.12
EPS (1 år frem)5.08

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)44.16%
Driftsmargin (TTM)14.00%
Fortjenstmargin (TTM)2.32%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter591.20M
Nettotilgodehavender331.40M
Omsætningsaktiver i alt2.08B
Goodwill3.48B
Immaterielle aktiver2.02B
Ejendomme, anlæg og udstyr0.00
Sum aktiver9.94B
Kreditor240.70M
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser1.09B
Sum gæld6.13B
Aktionærernes egenkapital3.81B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)837.80M
Investeringsudgifter (TTM)487.60M
Fri pengestrøm (TTM)350.20M
Udbetalt udbytte (TTM)100.00K

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast2.04%
Afkast af aktiver0.78%
Afkast af investeret kapital0.95%
Kontant afkast af investeret kapital4.31%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning215.20
Daglig høj216.90
Daglig lav215.20
Daglig volumen0K
Højeste gennem alle tider612.40
1 års analytiker estimat264.42
Beta0.94
EPS (TTM)1.12
Udbytte pr. aktie-
Ex-div dato28 Mar 2025
Næste dato for resultatpræsentation22 Jul 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
SRT3.FS&P500
Nuværende prisfald fra top notering-64.58%-3.04%
Højeste prisfald-99.61%-56.47%
Højeste efterår dato9 Oct 20029 Mar 2009
Gennemsnitlig fald fra toppen-73.85%-11.04%
Gennemsnitlig tid til nyt højdepunkt93 days12 days
Maks. tid til nyt højdepunkt5472 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
SRT3.F (Sartorius Aktiengesellschaft) company logo
Markedsværdi
7.55B
Markedsværdi kategori
Mid-cap
Beskrivelse
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
Personale
13762
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Germany
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Strategic Directions International (SDi), a leading provider of business intelligence for the analytical and life science instruments industry, has released its much-anticipated report, Company Market...
30. juni 2025
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is proud to launch the Sartorius PI Forum, taking place June 24–26, 2025, at the Royal Sonesta B...
24. juni 2025
Sartorius AG (SARTF) reports a promising Q1 2025 with significant sales growth and margin expansion, despite challenges in the Lab Products & Services division.
17. april 2025
Sartorius AG (SARTF) reports robust order growth and efficiency savings, despite facing headwinds in the Lab Products & Services division.
31. januar 2025
Sartorius AG (SARTF) reports a mixed quarter with strong order intake and cash flow improvements, despite facing sales revenue challenges and regional market pressures.
18. oktober 2024
Sartorius AG (SARTF) reports mixed results with strong order intake and efficiency gains, despite regional challenges and revised guidance.
9. oktober 2024